Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15384649 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2CA12TTRCA7CA14 | |
| SCHEMBL6033426 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2CA12TTRCA7CA14 | |
| SCHEMBL11337084 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2CA12TTRCA7CA14 | |
| Dioxane SCHEMBL1260650 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2CA12TTRCA7CA14 | |
| SCHEMBL24525605 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2CA12TTRCA7CA14 | |
| SCHEMBL25148134 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2CA12TTRCA7CA14 | |
| SCHEMBL2452972 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2CA12TTRCA7CA14 | |
| SCHEMBL12014324 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2CA12TTRCA7CA14 | |
| SCHEMBL21534078 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2CA12TTRCA7CA14 | |
| SCHEMBL2123718 | 0.96 | CA12 (0.45) | SMN1; SMN2CA12TTRCA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3939968-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | Medicinal Bioconvergence Research Center (KR) | 2022-01-19 | — | — | EP | disclosed |
| WO-2021026492-A1 | KAPPA OPIOID RECEPTOR PEPTIDE AMIDE AGONISTS | Humanwell Pharmaceutical US (US) | 2021-02-11 | — | — | WO | disclosed |
| US-20210040150-A1 | KAPPA OPIOID RECEPTOR PEPTIDE AMIDE AGONISTS | YICHANG HUMANWELL PHARMACEUTICALS CO., LTD. (CN) | 2021-02-11 | — | — | US | disclosed |
| EP-3721943-A1 | LIPIDS, LIPID COMPOSITIONS AND METHODS OF USING THEM | Novartis AG (CH) | 2020-10-14 | — | — | EP | disclosed |
| US-20190345154-A1 | NOVEL PYRIMIDINE DERIVATIVE HAVING ANTIMALARIAL ACTIVITY | CARNA BIOSCIENCES, INC. (JP) | 2019-11-14 | — | — | US | disclosed |
| EP-3542789-A2 | LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN-CODING RNA | GlaxoSmithKline Biologicals SA (BE) | 2019-09-25 | — | — | EP | disclosed |
| EP-3533795-A1 | NOVEL PYRIMIDINE DERIVATIVE HAVING ANTIMALARIAL ACTIVITY | Carna Biosciences Inc. (JP) | 2019-09-04 | — | — | EP | disclosed |
| EP-2611420-B1 | LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN-CODING RNA | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2019-03-27 | — | — | EP | disclosed |
| US-9301923-B2 | Lipids, lipid compositions, and methods of using them | NOVARTIS AG (CH) | 2016-04-05 | — | — | US | disclosed |
| US-9301923-B2 | Lipids, lipid compositions, and methods of using them | NOVARTIS AG (CH) | 2016-04-05 | — | — | US | disclosed |
| US-20140309277-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | NOVARTIS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-20140309277-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | NOVARTIS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-20130189351-A1 | LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN CODING RNA | NOVARTIS AG (CH) | 2013-07-25 | — | — | US | disclosed |
| US-20130189351-A1 | LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN CODING RNA | NOVARTIS AG (CH) | 2013-07-25 | — | — | US | disclosed |
| WO-2012031046-A2 | LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN-CODING RNA | NOVARTIS AG (CH) | 2012-03-08 | — | — | WO | disclosed |
| US-20110200582-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| US-20110200582-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| WO-2011076807-A2 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | NOVARTIS AG (CH) | 2011-06-30 | — | — | WO | disclosed |
| EP-0079920-A1 | NEW AZA-CROWN-ETHERS AND THEIR USE. | BORREGAARD IND (NO) | 1983-06-01 | — | — | EP | disclosed |
| WO-1982004253-A1 | NEW AZA-CROWN-ETHERS AND THEIR USE | DALE JOHANNES | 1982-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110200582-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | SGMS1, SGMS2, LIPC | SMN1; SMN2 2238/4885CA12 1111/4885TTR 1978/4885 |
| US-20130189351-A1 | LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN CODING RNA | NSUN3, RNMT, AGO2 | SMN1; SMN2 2162/4885CA12 4218/4885TTR 2435/4885 |
| US-20140309277-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | SGMS1, SGMS2, LIPC | SMN1; SMN2 2238/4885CA12 1111/4885TTR 1978/4885 |
| US-20190345154-A1 | NOVEL PYRIMIDINE DERIVATIVE HAVING ANTIMALARIAL ACTIVITY | UMPS, TYMS, TYMP | SMN1; SMN2 4430/4885CA12 4843/4885TTR 4143/4885 |
| US-20210040150-A1 | KAPPA OPIOID RECEPTOR PEPTIDE AMIDE AGONISTS | OPRK1, OPRL1, OPRD1 | SMN1; SMN2 1688/4885CA12 2194/4885TTR 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.